Outcome MeasureQuality of Life

WHOQOL-BREF

World Health Organization Quality of Life – BREF

3 Papers in Blossom

Outcome Data Across Studies

Reported results for WHOQOL-BREF across 1 study with quantitative data.

Outcome data across 4 study arm–timepoint observations
SD
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer
2020Secondary
Psilocybin exposure (both dose-sequence groups combined)(experimental)01613.90.8—
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer
2020Secondary
Psilocybin exposure (both dose-sequence groups combined)(experimental)1981615.30.8—
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer
2020Secondary
Psilocybin exposure (both dose-sequence groups combined)(experimental)11691515.50.8—
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer
2020Secondary
Psilocybin exposure (both dose-sequence groups combined)(experimental)16441414.70.8—

Papers Using WHOQOL-BREF

Open Accessindividual

LSD microdosing in major depressive disorder: results from an open-label trial

This open-label Phase IIa trial (n=19, 15 male) found that an 8-week regimen of microdosed LSD (8μg initially, then 6-20μg twice weekly) for major depressive disorder was well-tolerated with no serious adverse events or cardiac valvulopathy, achieved 59.5% reduction in MADRS scores sustained for six months, and had only one withdrawal due to anxiety.

Published
Journal
Neuropharmacology
Authors
Daldegan-Bueno, D., Donegan, C. J., Sumner, R. L., Forsyth, A., Evans, W. J., Alshakhouri, M., Reynolds, L. M, Roop, P., Ponton, R., Smith, T., Hoeh, N. R., Allen, N., Sundram, F., Menkes, D. B., Muthukumaraswamy, S.
Open Accessindividual

Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial

An open‑label pilot trial of two 25 mg psilocybin sessions with preparatory and integration psychotherapy for treatment‑resistant depression produced a clinically meaningful reduction in self‑rated depressive symptoms at three weeks (Hedges’ g = −1.27) that was maintained at 20 weeks, although individual responses varied (two sustained responders, three relapses, two non‑responders). Exploratory analyses linked pre‑dosing mindset, spiritual experiences and perceptual shifts to outcome trajectories, with adverse events consistent with prior studies and no serious adverse events.

Published
Journal
Therapeutic Advances in Psychopharmacology
Authors
Meikle, S., Carter, O., Liknaitzky, P., Johansen, L., Iyer, R., Strauss, N., Williams, M., Castle, D., Rossell, S. L., Ids, O.
Paywallindividual

Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer

In a 3.2–4.5 year follow-up of cancer patients (n=15) from a prior crossover trial, single-dose psilocybin-assisted psychotherapy produced large, sustained reductions in anxiety, depression, hopelessness, demoralisation and death anxiety, with about 60–80% maintaining clinically significant antidepressant or anxiolytic responses. Participants overwhelmingly reported enduring positive, personally meaningful and spiritually significant life changes.

Published
Journal
Journal of Psychopharmacology
Authors
Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., Ross, S.

Quick Facts

Full Name
World Health Organization Quality of Life – BREF
Domain
Quality of Life
Papers Indexed
3
Score Range
0–100
Interpretation
Higher = better
Unit
points
All Measures